ACRV today
$1.48+$0.02 (+1.37%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourDescending Triangle
15 minBullish
5 minExpanding
Daily trend turns up above $1.88
Key levels
Resistance$1.77
Resistance$1.58
Support$1.41
Support$1.27
Latest news & SEC filings
DealAcrivon Therapeutics buys ACR-525, a JAK1 inhibitor, from Aqilion AB
All ACRV news →About Acrivon Therapeutics
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing targeted cancer therapies. Its lead drug candidates include ACR-368 and ACR-2316. The company uses its AP3 precision medicine platform to match patients to treatments based on their tumor biology. It operates in the United States and relies on licensed intellectual property from third parties.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
Acrivon Therapeutics, Inc. (ACRV)
What Is the Price Target for ACRV?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is ACRV a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ACRV.
Start Free Trial →Is ACRV Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG
Fair Value
$2.40
17
Moat Score
NONE
1/9
Piotroski Score
-1.9
Altman Z-Score
What Is Smart Money Doing with ACRV?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Miller Mary | officer | Sale | 294 | $585.06 | Oct 5, 2026 |
| Levin Michaela | officer | Buy | 30,000 | - | Aug 31, 2026 |
| Blume-Jensen Peter | director officer | Sale | 14,036 | $31K | Aug 25, 2026 |
| Blume-Jensen Peter | director officer | Sale | 13,729 | $25K | May 21, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | director 10% owner | Buy | 9,366 | - | May 18, 2026 |
| TOMSICEK MICHAEL JOHN | director | Buy | 9,366 | - | May 18, 2026 |
| Shacham Sharon | director | Buy | 9,366 | - | May 18, 2026 |
| Palani Santhosh | director | Buy | 9,366 | - | May 18, 2026 |
| Magovcevic-Liebisch Ivana | director | Buy | 9,366 | - | May 18, 2026 |
| DiRocco Derek | director | Buy | 9,366 | - | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ACRV Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
15.13%
FCF Growth YoY
4.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for ACRV
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ACRV, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 13:43:49 | $1.56 | 1,381 | $$2K | BUY |
| 12:37:03 | $1.56 | 5,000 | $$8K | SELL |
| 12:32:22 | $1.58 | 4,999 | $$8K | BUY |
| 12:31:30 | $1.59 | 5,000 | $$8K | BUY |
| 20:59:47 | $1.45 | 1,100 | $$2K | BUY |
5 dark pool trades shown · $$27K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Acrivon Therapeutics, Inc. (ACRV) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ACRV — frequently asked questions
What is ACRV stock price today?
Acrivon Therapeutics, Inc. (ACRV) is at $1.48, up 1.37% (+$0.02) at the Nov 13, 2026 close.
Why is ACRV stock moving today?
Latest ACRV news — Nov 6, 2026: Acrivon Therapeutics buys ACR-525, a JAK1 inhibitor, from Aqilion AB
What do analysts rate ACRV?
Analyst ratings for ACRV: 7 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did ACRV beat earnings?
ACRV last reported on Aug 12, 2026: EPS -$0.43 vs -$0.50 expected — a beat of 14.4%.
Does ACRV pay a dividend?
ACRV does not currently pay a dividend.
What are ACRV support and resistance levels?
Support: $1.41, $1.27. Resistance: $1.58, $1.77, $1.96.
What are insiders doing with ACRV?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on ACRV?
Nov 6, 2026: Acrivon Therapeutics buys ACR-525, a JAK1 inhibitor, from Aqilion AB